Commenced FDA 510(k) clinical studies plan with Cliantha Research and remains on track for planned submission by the end of 2024 and planned entry into the US in 2025 Secured 26 new customer accounts ...

INBS surged on strategic manufacturing partnership and revenue growth, but pulled back after announcing plans to raise $10 ...

CCC Intelligent Solutions Inc. (CCC), a subsidiary of CCC Intelligent Solutions Holdings Inc., is a leading SaaS platform provider for the multi-trillion-dollar insurance economy, creating intelligent ...

Record quarterly revenue of $1.11 million, an increase of 32% sequentially and 28% year-over-year, driven by consumable cartridge sales and customer base expansion Gross profit margins increased 690 ...

NEW YORK, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing ...

Company advanced efforts to secure U.S. FDA 510(k) clearance to advance on path towards planned U.S. market expansion beyond Forensic Use Only settings Fourth quarter sequential and year-on-year ...

CHICAGO--(BUSINESS WIRE)--CCC Intelligent Solutions Holdings Inc. (“CCC” or the “Company”) (NYSE: CCCS), a leading SaaS platform for the P&C insurance economy, today announced its financial results ...

Year-over-year revenue increased 80% for the fiscal third quarter and 193% for the nine months ended March 31, 2024 Cash and cash equivalents as of March 31, 2024, was $9.40 million Commenced FDA ...

"Our first quarter results show accelerating momentum of our business model and the growing market adoption internationally of our non-invasive drug screening technology," said Harry Simeonidis, ...